|Videos|June 24, 2020

Contagion Live News Network: Coronavirus Guidelines Discourage Hydroxychloroquine Outside Trials

Video briefing on the day's top infectious disease news.

In light of evolving knowledge about SARS-CoV-2, the Infectious Diseases Society of America (IDSA) has updated guidelines for treating coronavirus 2019 (COVID-19), the illness caused by SARS-CoV-2 infection.

Given research into SARS-CoV-2 is taking place at unprecedented speed, the panel of IDSA experts had to decide on current best practices using science which is still in motion.

Recent updates include:

1. New recommendations on the use of remdesivir.

2. Revised recommendations on hydroxychloroquine and hydroxychloroquine/azithromycin combination therapy.

3. New recommendations for famotidine.

4. Revised recommendations concerning convalescent plasma for treatment of COVID-19.

In other news, a recent review of electronic health data revealed a 42% drop in emergency department visits during 4 weeks of the pandemic. Public health officials are concerned that fear over the coronavirus has led to patients delaying care for life-threatening illness.

And lastly, we shared a clip in which Dr. Patrick Soon-Shiong of ImmunityBio.explains how the firm’s coronavirus vaccine research benefits from drawing on a background in cancer.


Related to this article

New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.